The far more nuanced and precise data produced by single cell analyses will allow for better understanding of
pancreatic islet function and dysfunction at the cellular level.
Not exact matches
Dr. Kulkarni's research focuses on investigating signaling pathways impacting growth and
function of
pancreatic islet cells with the long - term goal of improving therapeutic approaches for the treatment of type 1 and type 2 diabetes and obesity - associated conditions.
This has been evidenced by 1) increased acinar cell necrosis, 2) increased serum amylase and lipase, 3) higher hepatic damage, 4) altered liver
function test, 5) increased kidney damage, 6) increase in serum urea and creatinine, 7) altered distribution of
pancreatic cells, 8) increased vacoulation and irregular
islets, and 9) mild fibrosis in exocrine regions.
ViaCyte is developing a drug delivery system that enables implanted
pancreatic progenitor cells to survive and differentiate into
functioning insulin - producing
islet cells.
Type 1 diabetes usually occurs early in life and affects more than one million Americans who are unable to manufacture their own insulin because their
pancreatic islets do not
function.
Type 1 Diabetes mellitus (T1D) is an autoimmune disorder characterized by a loss of
function of insulin producing beta cells in
pancreatic islets of langerhans leading to insulin insufficiency.
Vanderbilt University, «Improving isolation of
pancreatic islets in T1D to assess alpha cell
function and gene expression,» led by Drs. Al Powers and David Harlan (University of Massachusetts Medical School)